CLDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Celldex Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.638. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-10.17 for the trailing ten years ended in Dec. 2023.
During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Celldex Therapeutics was 28.80% per year. The lowest was -9.90% per year. And the median was 6.55% per year.
As of today (2024-04-28), Celldex Therapeutics's current stock price is $36.30. Celldex Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-10.17. Celldex Therapeutics's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Celldex Therapeutics's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | -11.35 | -11.15 | -10.87 | -10.56 | -10.17 |
For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Celldex Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.638 | / | 129.4194 | * | 129.4194 | |
= | -0.638 |
Current CPI (Dec. 2023) = 129.4194.
Celldex Therapeutics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | -5.389 | 99.695 | -6.996 |
201406 | -3.652 | 100.560 | -4.700 |
201409 | -4.574 | 100.428 | -5.894 |
201412 | -3.748 | 99.070 | -4.896 |
201503 | -5.542 | 99.621 | -7.200 |
201506 | -4.007 | 100.684 | -5.151 |
201509 | -4.436 | 100.392 | -5.719 |
201512 | -2.152 | 99.792 | -2.791 |
201603 | -5.387 | 100.470 | -6.939 |
201606 | -5.252 | 101.688 | -6.684 |
201609 | -3.689 | 101.861 | -4.687 |
201612 | -2.917 | 101.863 | -3.706 |
201703 | -4.358 | 102.862 | -5.483 |
201706 | -2.603 | 103.349 | -3.260 |
201709 | -2.851 | 104.136 | -3.543 |
201712 | -2.164 | 104.011 | -2.693 |
201803 | -3.018 | 105.290 | -3.710 |
201806 | -1.804 | 106.317 | -2.196 |
201809 | -1.324 | 106.507 | -1.609 |
201812 | -1.339 | 105.998 | -1.635 |
201903 | -1.091 | 107.251 | -1.317 |
201906 | -0.813 | 108.070 | -0.974 |
201909 | -0.738 | 108.329 | -0.882 |
201912 | -0.674 | 108.420 | -0.805 |
202003 | -0.709 | 108.902 | -0.843 |
202006 | -0.549 | 108.767 | -0.653 |
202009 | -0.306 | 109.815 | -0.361 |
202012 | -0.138 | 109.897 | -0.163 |
202103 | -0.471 | 111.754 | -0.545 |
202106 | -0.305 | 114.631 | -0.344 |
202109 | -0.364 | 115.734 | -0.407 |
202112 | -0.318 | 117.630 | -0.350 |
202203 | -0.537 | 121.301 | -0.573 |
202206 | -0.490 | 125.017 | -0.507 |
202209 | -0.757 | 125.227 | -0.782 |
202212 | -0.467 | 125.222 | -0.483 |
202303 | -0.617 | 127.348 | -0.627 |
202306 | -0.584 | 128.729 | -0.587 |
202309 | -0.405 | 129.860 | -0.404 |
202312 | -0.638 | 129.419 | -0.638 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Celldex Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Garry Arthur Neil | director | 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104 |
Cheryl Cohen | director | C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105 |
Rita Jain | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Tibor Keler | officer: Sen. VP & Ch Scientific Off. | 30 PARK ROAD, OTTSVILLE PA 18942 |
Sarah Cavanaugh | officer: SVP of Corp. Affairs & Admin. | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Diane C. Young | officer: SVP, Chief Medical Officer | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
Anthony S Marucci | director, officer: President and CEO | 66 COLD HILL DRIVE, MENDAHM NJ 07945 |
Richard M. Wright | officer: Sr. VP & CCO | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Samuel Bates Martin | officer: SVP and CFO | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Margo Heath-chiozzi | officer: SVP of of Regulatory Affairs | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Elizabeth Crowley | officer: SVP, Chief Product Dev Officer | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Freddy A. Jimenez | officer: SVP & General Counsel | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
James J Marino | director | C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940 |
Keith L Brownlie | director | 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591 |
Gerald Phd Mcmahon | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
From GuruFocus
By Marketwired • 07-11-2023
By Marketwired • 11-05-2023
By GuruFocus Research • 11-04-2023
By GlobeNewswire GlobeNewswire • 02-26-2023
By sperokesalga sperokesalga • 06-10-2023
By sperokesalga sperokesalga • 06-08-2023
By Marketwired • 08-08-2023
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 02-15-2023
By GlobeNewswire • 11-27-2023